The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Managing lenalidomide-refractory myeloma patients
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses treatment approaches for lenalidomide-refractory myeloma patients. Dr Ramasamy highlights the combination of a monoclonal antibody plus a proteasome inhibitor and dexamethasone, which is currently used in the UK. Following this, Dr Ramasamy mentions novel combinations going through NICE approval and the importance of clinical trials in providing more options for lenalidomide-refractory patients. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
